Literature DB >> 24103107

Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.

Rocio Pérez-Iglesias1, Obdulia Martínez-García, Gema Pardo-Garcia, Jose Antonio Amado, M Teresa Garcia-Unzueta, Rafael Tabares-Seisdedos, Benedicto Crespo-Facorro.   

Abstract

Data on the long-term metabolic side-effects associated with antipsychotics are scarce. Prospective longitudinal studies in medication-naive patients with a first episode of psychosis are a valuable source of information as they provide an assessment prior to the antipsychotic exposure and minimize the effect of potential confounding factors. The aim of this study was to assess the course of weight gain and the incidence of metabolic abnormalities during the first 3 yr of antipsychotic treatment. Data were collected from a cohort of 170 first-episode psychosis patients. They were randomly assigned to haloperidol (32%); olanzapine (32%) and risperidone (36%). The dose used was flexible. The initial antipsychotic treatment was changed when required, based on clinical response and tolerability. The results showed that the mean weight gain at 3 yr was 12.1 kg (s.d. = 10.7). It appeared to increase rapidly during the first year (85% of the total mean weight gain) and then stabilized gradually over time. Total cholesterol, LDL-cholesterol and triglyceride levels followed a similar trajectory with a significant increase only during the first year. No significant changes were detected in the mean values of glycaemic parameters. Two patients with a family history of diabetes developed diabetes type II. At short-term the factors positively associated with weight gain were lower body mass index, male gender and olanzapine treatment. At long-term, functional status and clinical response were the main predictors. The results of our study indicate that the first year of antipsychotic treatment is a critical period for weight gain and metabolic changes. Identification of weight gain patterns may help to inform studies that aim to prevent or mitigate the metabolic adverse events associated with antipsychotic therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24103107     DOI: 10.1017/S1461145713001053

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  34 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Weight Gain and Its Correlates Among Forensic Inpatients.

Authors:  N Zoe Hilton; Elke Ham; Carol Lang; Grant T Harris
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

3.  Using Smartphone Apps to Promote Psychiatric and Physical Well-Being.

Authors:  Cathaleene Macias; Trishan Panch; Yale M Hicks; Jason S Scolnick; David Lyle Weene; Dost Öngür; Bruce M Cohen
Journal:  Psychiatr Q       Date:  2015-12

4.  Cannabis use and metabolic syndrome among clients with first episode psychosis.

Authors:  Erik Stiles; Karl C Alcover; Bryan Stiles; Oladunni Oluwoye; Michael G McDonell
Journal:  Early Interv Psychiatry       Date:  2020-09-02       Impact factor: 2.732

5.  The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole.

Authors:  Andreas Schreiner; Paul Bergmans; Pierre Cherubin; Ludger Hargarter
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-14

6.  Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.

Authors:  María José Morlán-Coarasa; María Teresa Arias-Loste; Víctor Ortiz-García de la Foz; Obdulia Martínez-García; Carmen Alonso-Martín; Javier Crespo; Manuel Romero-Gómez; Emilio Fábrega; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2016-09-12       Impact factor: 4.530

Review 7.  Diabetes and Schizophrenia.

Authors:  Jaana Suvisaari; Jaakko Keinänen; Saana Eskelinen; Outi Mantere
Journal:  Curr Diab Rep       Date:  2016-02       Impact factor: 4.810

8.  Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.

Authors:  Javier Vázquez-Bourgon; Rocío Pérez-Iglesias; Víctor Ortiz-García de la Foz; Paula Suárez Pinilla; Álvaro Díaz Martínez; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-10-26       Impact factor: 4.530

9.  Body mass, cardiovascular risk and metabolic characteristics of young persons presenting for mental healthcare in Sydney, Australia.

Authors:  Elizabeth M Scott; Daniel F Hermens; Django White; Sharon L Naismith; Jeanne GeHue; Bradley G Whitwell; Nick Glozier; Ian B Hickie
Journal:  BMJ Open       Date:  2015-03-27       Impact factor: 2.692

10.  Behavioral outputs of negative symptom domains of schizophrenia.

Authors:  Octavia Căpățînă; Mihaela Fadgyas Stănculete; Ioana Micluția
Journal:  Exp Ther Med       Date:  2021-05-26       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.